Welcome to our dedicated page for Axsome Therapeut news (Ticker: AXSM), a resource for investors and traders seeking the latest updates and insights on Axsome Therapeut stock.
Axsome Therapeutics (AXSM) is a clinical-stage biopharmaceutical leader developing innovative therapies for central nervous system disorders. This news hub provides investors and healthcare professionals with timely updates on clinical trial progress, regulatory milestones, and research breakthroughs.
Access comprehensive coverage of AXSM's developments including FDA submissions, partnership announcements, and scientific presentations. Our curated news collection features essential updates on depression treatments, narcolepsy therapies, and Alzheimer's-related research programs.
Key information categories include:
• Clinical trial results and phase updates
• Regulatory filings and approvals
• Research collaborations and licensing agreements
• Financial performance and strategic initiatives
Bookmark this page for direct access to verified Axsome Therapeutics announcements and expert analyses. Stay informed about pipeline developments in neurological treatment innovation through our continuously updated news repository.
Axsome Therapeutics, Inc. (NASDAQ: AXSM) will be represented by Chief Executive Officer, Dr. Herriot Tabuteau, at two upcoming investor conferences. The company focuses on developing novel therapies for central nervous system disorders. The presentations will take place at the RBC Capital Markets 2024 Global Healthcare Conference on May 14 and the Bank of America 2024 Healthcare Conference on May 16. Investors can watch the events live on the company's website.
Axsome Therapeutics reported strong financial results for the first quarter of 2024, with total net product revenue of $75.0 million, representing significant year-over-year growth. The company announced positive Phase 3 trial results for AXS-12 in narcolepsy, with other key pipeline programs progressing well. However, the increase in research and development expenses, higher selling, general, and administrative expenses, and a net loss of $68.4 million for the quarter are some challenges highlighted in the financial report.
FAQ
What is the current stock price of Axsome Therapeut (AXSM)?
What is the market cap of Axsome Therapeut (AXSM)?
